Chloe Kent
Reporter
Chloe is an award-winning journalist who has specialized in health reporting throughout her career, with a particular focus on women's health and access to medicine. Before joining Generics Bulletin she worked for B2B publishing consortium Verdict, writing about medical technology and pharmaceuticals. Having graduated from the University of York, she went on to train as a journalist with the Press Association.
Latest From Chloe Kent
ANI Brings In Record Revenues As Cortrophin Rollout Ploughs Ahead
ANI Pharmaceuticals has recorded its highest-ever quarterly revenue of $73.9m during Q2, following the launch of its cortrophin gel and a substantial growth in generics revenue.
Amneal Expects Host Of New Launches To Drive Firm To Success
Despite a couple of setbacks during Q2, Amneal has sustained continual growth across its business, particularly in the injectables space.
One Year On, US FDA Generic Drug Cluster Focuses On Facilitating Collaboration
Following its inaugural year, the FDA’s Generic Drug Cluster has formed data sharing arrangements concerning a number of vital indications.
Lack Of Interchangeability No Barrier For Amjevita, Says Amgen Executive
While Amgen’s Amjevita (adalimumab-atto) has yet to secure an interchangeability designation, company executives appear confident this will have little impact on their Humira biosimilar’s competitiveness overall.
Who’s Hired? Makov To Step Away From Sun Pharma After 10 Years
While Israel Makov steps away from Sun Pharmaceuticals, Mayne and Avet bring in new executives, Amneal appoints a new director and the AAM promotes a loyal colleague.
One Year On, FDA Generic Drug Cluster Focuses On Facilitating Collaboration
Following its inaugural year, the FDA’s Generic Drug Cluster has formed data sharing arrangements concerning a number of vital indications.